Feed RANI
RA

Rani Therapeutics Holdings, Inc.

RANI · NASDAQ

$0.86 +1.41% (+$0.01)
1M +1.29%
Market Cap $55.6M
P/E Ratio -
Div. Yield -
ROE 129.93%

Bulios Fair Price

$1.21

40.4% upside

Current Price

$0.86

Undervalued Fair Value Overvalued

According to Bulios Fair Price, RANI is currently undervalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
5/9
Valuation
50 /100
Fair
P/S 11.41x
P/B 1.42x
P/E N/A
Growth
7 /100
Declining
Book val. growth 3.61%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak
Gross margin 96.70%
Net margin 618.02%
Op. margin 675.81%
Quality
1 /100
Poor
ROIC 63.96%
ROE 129.93%
ROA 49.54%
Debt
69 /100
Low
Debt/Equity 0.09x
Current ratio 5.31x
Int. coverage -27.97x
Stability
65 /100
Moderate
Beta 0.71x
EPS volatility 30.69%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RANI
Online

About the company

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Sector

Healthcare

Industry

Biotechnology

CEO

Talat Imran

Employees

70

Headquarters

San Jose

Upcoming events

05 NOV

Earnings

Upcoming earnings report

47d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.